Skip to main content
SpringerLink
Log in

A single-centre retrospective case series of Anakinra for incident calcium pyrophosphate deposition disease

  • BRIEF REPORT
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

In this 2-year retrospective case series, we characterise the calcium pyrophosphate deposition disease (CPPD) inpatient cohort at a single centre and assess the efficacy and safety of anakinra in its treatment. Adult inpatients with CPPD between 1st September 2020 and 30th September 2022 were identified by ICD-10 codes and confirmed based on clinical diagnosis and either CPP crystals on aspirate or chondrocalcinosis on imaging. Charts were reviewed for demographic, clinical, biochemical data, treatment choice, and response. Response to treatment was determined from chart documentation and calculated from time of first CPPD treatment. Daily responses to anakinra were recorded if anakinra was used. Seventy patients accounting for 79 cases of CPPD were identified. Twelve cases received anakinra, whilst 67 cases received conventional therapy only. Patient receiving anakinra were predominantly male, had multiple comorbidities, and had higher CRPs and serum creatinine when compared to the non-anakinra group. Anakinra was rapidly effective with the mean time to substantial and complete response being 1.7 and 3.6 days respectively. Anakinra was well tolerated. This study adds to the small amount of retrospective data present about the use of anakinra in CPPD. We observed a rapid response to anakinra in our cohort with minimal adverse drug reactions.

Key Points

• Treatment of CPPD with anakinra appears to be rapidly efficacious without safety concerns.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P et al (2007) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63(2):136–147

    Article  CAS  PubMed  Google Scholar 

  2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456):15–19

    Article  PubMed  PubMed Central  Google Scholar 

  3. Yao TC, Huang YW, Chang SM, Tsai SY, Wu AC, Tsai HJ (2020) Association between oral corticosteroid bursts and severe adverse events : a nationwide population-based cohort study. Ann Intern Med 173(5):325–330

    Article  PubMed  Google Scholar 

  4. Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM et al (2017) Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 357:j1415

    Article  PubMed  PubMed Central  Google Scholar 

  5. Terkeltaub RA (2009) Colchicine update: 2008. Semin Arthritis Rheum 38(6):411–419

    Article  CAS  PubMed  Google Scholar 

  6. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L (2010) Anakinra’s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 40(3):210–214

    Article  CAS  PubMed  Google Scholar 

  7. Desmarais J, Chu C-Q (2019) Utility of anakinra in acute crystalline diseases: a retrospective study comparing a university hospital with a Veterans Affairs medical center. J Rheumatol 46(7):748–750

    Article  CAS  PubMed  Google Scholar 

  8. Dumusc A, Pazar Maldonado B, Benaim C, Zufferey P, Aubry-Rozier B, So A (2021) Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: a randomized controlled double-blinded pilot study. Joint Bone Spine 88(2):105088

    Article  PubMed  Google Scholar 

  9. Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC (2013) Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken) 65(8):1381–1384

    Article  CAS  PubMed  Google Scholar 

  10. Liew JW, Gardner GC (2019) Use of anakinra in hospitalized patients with crystal-associated arthritis. J Rheumatol 46(10):1345–1349

    Article  CAS  PubMed  Google Scholar 

  11. Ottaviani S, Moltó A, Ea HK, Neveu S, Gill G, Brunier L et al (2013) Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 15(5):R123

    Article  PubMed  PubMed Central  Google Scholar 

  12. Palma C, Topping T, Tabechian D, editors (2016) Anakinra is effective and well tolerated in medically complex patients including transplant recipients with gout. Arthritis & Rheumatology: Hoboken NJ USA

  13. Petite SE (2017) Effectiveness of anakinra in acute gout: a retrospective review of initial and refractory therapy. Am J Ther 24(5):e633–e634

    Article  PubMed  Google Scholar 

  14. Sharma E, Terkeltaub R, editors (2017) A case control study of anakinra use for acute gout in a VA patient cohort reveals association with East Asian descent, high urate burden, and increased co-morbidities and all-cause mortality. Arthritis & Rheumatology; Hoboken NJ USA

  15. So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28

    Article  PubMed  PubMed Central  Google Scholar 

  16. Thueringer JT, Doll NK, Gertner E, editors (2015) Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum 45(1):81–85

  17. Vitale A, Cantarini L, Rigante D, Bardelli M, Galeazzi M (2015) Anakinra treatment in patients with gout and type 2 diabetes. Clin Rheumatol 34(5):981–984

    Article  PubMed  Google Scholar 

  18. Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling Koskinen L, Sparve E et al (2021) A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol 73(8):1533–1542

    Article  CAS  PubMed  Google Scholar 

  19. Cipolletta E, Di Matteo A, Scanu A, Isidori M, Di Battista J, Punzi L et al (2020) Biologics in the treatment of calcium pyrophosphate deposition disease: a systematic literature review. Clin Exp Rheumatol 38(5):1001–1007

    PubMed  Google Scholar 

  20. Thomas M, Forien M, Palazzo E, Dieudé P, Ottaviani S (2019) Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: a retrospective study of 33 cases. Clin Rheumatol 38(2):425–430

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the research support staff of the Illawarra Shoalhaven Local Health District for their valuable administrative support. We also thank Professors Peter Wong and Marissa Lassere for their suggestions and assistance with revisions.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Wollongong Hospital, Wollongong, NSW, Australia

    Alwin Lian & John Riordan

  2. Graduate School of Medicine, University of Wollongong, Wollongong, NSW, Australia

    Apoorva Shandilya

Authors
  1. Alwin Lian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Apoorva Shandilya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Riordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alwin Lian.

Ethics declarations

Disclosures

None.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lian, A., Shandilya, A. & Riordan, J. A single-centre retrospective case series of Anakinra for incident calcium pyrophosphate deposition disease. Clin Rheumatol 42, 1833–1837 (2023). https://doi.org/10.1007/s10067-023-06573-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-023-06573-0

Keywords

Search

Navigation